Spain Supreme Court rejects compensation for thalidomide victims

September 23, 2015

Spain's Supreme Court on Wednesday upheld a lower court ruling that the German maker of pregnancy drug thalidomide does not have to compensate Spaniards who suffered birth defects from it.

The court confirmed a Madrid provincial tribunal's acceptance in October 2014 of an appeal by the company Grunenthal that the statute of limitations for the plaintiffs' case had expired.

A lower court had in November 2013 ordered the firm to pay 20,000 euros ($22,300) for each percentage point of disability suffered by the victims as recognised by Spain's health ministry but Grunenthal appealed.

It did not specify exactly how many plaintiffs there were nor how much the compensation and costs would add up to in total.

The case was brought forward in 2012 by Avite, an association representing Spaniards born with severe defects after their mothers took the drug during their pregnancies to treat morning sickness.

It had sought compensation of 204 million euros for its members.

Supreme Court justices voted eight to one to uphold the lower court's ruling despite a recommendation from the public prosecutor's office that it accept the plaintiffs' appeal.

But the court left the door open for future civil claims of compensation "based on the appearance of unknown damage or aggravation of existing damage".

"We will continue the fight and will go before the Constitutional Court and the European Court of Human Rights," a lawyer for the victims, Ignacio Marinez, told reporters.

Thalidomide was originally marketed as a sedative, but from the late 1950s was prescribed to women around the world to combat morning sickness.

Many of the children of the mothers who took the drug were born with abnormally short limbs and in some cases without any arms, legs or hips. In late 1961 the drug was withdrawn from the British and German markets.

But it continued to be sold in other countries including Spain, Canada and Japan for several more months.

The drug is estimated to have caused deformities in 10,000 to 20,000 babies in some 40 countries.

Avite estimates that up to 3,000 babies may have been born with deformities in Spain because of the drug.

Explore further: German thalidomide maker wins appeal in Spain compensation case (Update)

Related Stories

German thalidomide maker wins appeal in Spain compensation case (Update)

October 22, 2014
A Spanish court has upheld an appeal by the German maker of the banned pregnancy drug thalidomide and scrapped a previous ruling ordering the firm to compensate Spaniards who suffered birth defects from it in the 1960s.

Five decades on, Spain court convicts thalidomide maker

November 20, 2013
A court ordered the German maker of the banned pregnancy drug thalidomide to compensate Spanish victims who suffered birth defects from it in the 1960s, in a ruling released Wednesday.

Victims: Thalidomide sold in Spain post-withdrawal

May 8, 2013
(AP)—Spanish victims of thalidomide on Wednesday published documents they claim prove a German drug company kept distributing the notorious drug in Spain six months after it was taken off the market in other countries.

Spain court hears case against German maker of Thalidomide (Update)

October 14, 2013
A Madrid court on Monday heard Spain's first lawsuit against German firm Grunenthal, the manufacturer of the morning sickness drug thalidomide which caused birth defects in thousands of babies.

Frances Kelsey, doctor who opposed thalidomide, dies at 101

August 9, 2015
Frances Kelsey, a Canadian doctor known for her tenacity in keeping a dangerous drug given to pregnant women off the U.S. market, has died at age 101.

Recommended for you

Opioids given too easily to children: study

July 16, 2018
(HealthDay)—Many children are prescribed powerful opioid painkillers they don't really need, putting them and those around them at risk, a new study shows.

Study reveals opioid patients face multiple barriers to treatment

July 12, 2018
In areas of the country disproportionately affected by the opioid crisis, treatment programs are less likely to accept patients paying through insurance of any type or accept pregnant women, a new Vanderbilt study found.

Report details possible conflict of interest issues for FDA advisors

July 6, 2018
Charles Piller, a contributing correspondent for the journal Science, has published a Feature piece in the journal detailing what he describes as possible conflicts of interest issues by people who serve as advisors to the ...

Opioid epidemic responses overlook gender

July 5, 2018
Yale health experts warn that current efforts to confront the growth of opioid addiction and overdose deaths must better incorporate an understanding of how women fit into this epidemic.

Study finds no strong evidence that cannabis reduces chronic pain

July 4, 2018
A four-year study suggests medicinal cannabis is not as effective at relieving chronic non-cancer pain as commonly assumed.

Expanding primary care buprenorphine treatment could curb opioid overdose crisis

July 4, 2018
Expanding the availability of medication treatment for opioid use disorder in primary care settings would be a major step toward reducing overdose deaths, write two physicians specializing in addiction medicine and health ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.